Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:32:13.618Z.
Consensus retrieved: 2026-10-06T12:31:01.545Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:32:13.618Z.
Quote observation: 2026-10-06T14:30:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a3e1feeb410069f07e4350e21f058018b4d4b1a35d97054c3a706da9d6a2f8d
Forward PE Ratio (N/A) = Dated Quote Price ($0.50) / Consensus Forward EPS ($-0.40)
FORWARD PE RATIO
N/A
Humacyte, Inc.
Market Cap
$84.13M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Humacyte, Inc. (HUMA) | $84.13M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.15M | N/A |
| Nutriband Inc. (NTRB)vs › | $84.24M | 4.41 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.58M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.55M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.69M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.61M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.83M | 8.80 |
| LENSAR Inc (LNSR)vs › | $81.43M | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 7.44 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.40 | $-0.46 – $-0.37 | 4 | n/m |
| 2027-12-31 | $-0.24 | $-0.29 – $-0.21 | 4 | n/m |
| 2028-12-31 | $-0.05 | $-0.15 – $0.10 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
